A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Discover how the dry air of winter affects your nose and how to combat the drying out with helpful tips and treatments.

The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a ...

PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...

PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targe ...

The UK-based consumer healthcare company will be modernizing its facility along Brook Road, where it conducts R&D for such ...

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...

Researchers delivered a dose of the “love hormone” oxytocin via a nasal spray to participants and found that it decreased ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

TikTok went dark on Sunday for US users as a new law banning the app took effect at midnight.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.